Back to results
US 2022/0064328 A1Published application
Formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalation
AssigneeAnovent Pharmaceutical (U.S.), LLC
InventorsCai Gu Huang, Hitesh Bhagavanbhai Mangukiya
Life of this patent
Estimating the term…
Abstract
The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.
Claims19
A liquid, propellant-free pharmaceutical formulation comprising:
- (A) caplacizumab in an amount ranging from about 0.01 mg/ml to about 100 mg/ml and (B) at least one pharmaceutically acceptable pH-adjusting agent.
Dependencies are inferred from the claim text.